HEARTBEAM INC
BEATNASDAQTrading Snapshot
- Day Range
- $0.27 β $0.30
- 52-Week Range
- $0.27 β $4.00
- Volume (shares)
- 659,767
- Avg Volume (shares)
- β
- Shares Outstanding
- 56.4M
- Next Earnings
- 2027-03-11
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-0.51
- Dividend Yield
- β
- Dilution (1yr)
- +26.0%
HEARTBEAM INC
BEATAbout HEARTBEAM INC
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks -- LRN, TPR, BEAT, QS, ALTO -- with increasing P/E ratios to try out an out-of-the-box approach.

HeartBeam, Inc. (BEAT) Q3 2026 Earnings Call Transcript
HeartBeam, Inc. (BEAT) Q3 2026 Earnings Call Transcript

HeartBeam Reports Third Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2026 Results.

HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time.

HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG.

HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026.